Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 839706-07-9 Chemical Structure| 839706-07-9

Structure of GNF-7
CAS No.: 839706-07-9

Chemical Structure| 839706-07-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GNF-7 inhibits Bcr-Abl WT and Bcr-Abl T315I with IC50 of 133 nM and 61 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GNF-7

CAS No. :839706-07-9
Formula : C28H24F3N7O2
M.W : 547.53
SMILES Code : O=C(NC1=CC=C(C)C(N2CC3=CN=C(NC4=CC=C(C)N=C4)N=C3N(C)C2=O)=C1)C5=CC=CC(C(F)(F)F)=C5
MDL No. :MFCD18251569
InChI Key :SZNYUUZOQHNEKB-UHFFFAOYSA-N
Pubchem ID :11478363

Safety of GNF-7

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H301
Precautionary Statements:P301+P310
Class:6.1
UN#:2811
Packing Group:

Related Pathways of GNF-7

RTK

Isoform Comparison

Biological Activity

Target
  • Abl

    E255V, IC50:122 nM

    M351T, IC50:133 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
Hela cells 50 µM 2 days GNF-7 treatment reduced miR-21-5p levels to ~35% compared to the controls. Sci Rep. 2023 Mar 31;13(1):5244.
OCI-AML3 (NRAS-Q61L) 0.229 ± 0.010 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited NRAS-Q61L mutated OCI-AML3 cells Front Oncol. 2021 Dec 9;11:768022.
HT-29 (KRAS-Q61L) 0.938 ± 0.034 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-Q61L mutated HT-29 cells Front Oncol. 2021 Dec 9;11:768022.
MDA-MB-231 (KRAS-G13D) 0.296 ± 0.039 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G13D mutated MDA-MB-231 cells Front Oncol. 2021 Dec 9;11:768022.
SW480 (KRAS-G12V) 0.760 ± 0.063 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12V mutated SW480 cells Front Oncol. 2021 Dec 9;11:768022.
DU-145 (KRAS-G12V) 0.288 ± 0.057 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12V mutated DU-145 cells Front Oncol. 2021 Dec 9;11:768022.
AsPC-1 (KRAS-G12D) 0.448 ± 0.027 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12D mutated AsPC-1 cells Front Oncol. 2021 Dec 9;11:768022.
H358 (KRAS-G12C) 0.922 ± 0.093 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited KRAS-G12C mutated H358 cells Front Oncol. 2021 Dec 9;11:768022.
Ba/F3 cells (NRAS-G12V transformed) 0.396 ± 0.036 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited NRAS-G12V transformed Ba/F3 cells Front Oncol. 2021 Dec 9;11:768022.
Ba/F3 cells (NRAS-G12D transformed) 0.250 ± 0.026 (GI50 ) 72 hours Evaluate anti-proliferative activity, results showed GNF-7 inhibited NRAS-G12D transformed Ba/F3 cells Front Oncol. 2021 Dec 9;11:768022.
WM3629 0.21 ± 0.00 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on WM3629 cells Int J Mol Sci. 2021 Apr 6;22(7):3783.
WM3670 0.13 ± 0.01 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on WM3670 cells Int J Mol Sci. 2021 Apr 6;22(7):3783.
C8161 0.02 ± 0.00 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on C8161 cells Int J Mol Sci. 2021 Apr 6;22(7):3783.
A375 0.06 ± 0.00 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on A375 cells Int J Mol Sci. 2021 Apr 6;22(7):3783.
SK-MEL-28 0.15 ± 0.02 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on SK-MEL-28 cells Int J Mol Sci. 2021 Apr 6;22(7):3783.
SK-MEL-2 0.23 ± 0.08 µM (GI50 ) 72 hours Evaluate anti-proliferative activity, GNF-7 showed anti-proliferative activity on SK-MEL-2 cells Int J Mol Sci. 2021 Apr 6;22(7):3783.
HEK293T >10 µM To evaluate the growth inhibitory activity of GNF-7 against non-cancer cells J Med Chem. 2010 Aug 12;53(15):5439-48.
SW620 0.001 µM To evaluate the growth inhibitory activity of GNF-7 against colon cancer cells J Med Chem. 2010 Aug 12;53(15):5439-48.
Colo205 0.005 µM To evaluate the growth inhibitory activity of GNF-7 against colon cancer cells J Med Chem. 2010 Aug 12;53(15):5439-48.
Ba/F3-T315I-Bcr-Abl 11 nM To evaluate the antiproliferative activity of GNF-7 against T315I Bcr-Abl mutant cells J Med Chem. 2010 Aug 12;53(15):5439-48.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice BaLb/C Mice Oral 10 mg/kg or 20 mg/kg Once daily To evaluate the inhibitory effect of GNF-7 on T315I-Bcr-Abl-dependent tumor growth J Med Chem. 2010 Aug 12;53(15):5439-48.
C57BL/6 mice DSS-induced colitis model Intraperitoneal injection 5 mg/kg Once daily for 7 days To evaluate the therapeutic potential of 7a in DSS-induced colitis model. 7a treatment significantly improved clinical symptoms, including disease activity index (DAI) scores and recovery of colon length shortening. J Enzyme Inhib Med Chem. 2022 Dec;37(1):1257-1277

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.83mL

0.37mL

0.18mL

9.13mL

1.83mL

0.91mL

18.26mL

3.65mL

1.83mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories